لماذا يرتفع سعر سهم RESMED؟
المتفائلون يقولون
Capital allocation
Sale of MatrixCare provides cash earmarked for accelerated share repurchases, which could support per‑share returns and bolster shareholder value.
Portfolio optimization
Divesting the underperforming residential care software business narrows focus on core sleep apnea solutions, improving portfolio quality and supporting a return to stronger SaaS revenue growth.
Strategic acquisition
Acquisition of a restless leg syndrome specialist broadens clinical offerings and creates cross‑selling opportunities with obstructive sleep apnea treatments, supporting revenue expansion.
Product safety and supply
Field safety notice for certain ventilators and severely limited availability of replacement circuit boards risk therapy interruptions and constrain repair capacity and device supply.
Earnings dilution and accounting loss
Sale of the software business at a price below its original purchase may create a non‑cash accounting loss and, combined with the Noctrix deal, is expected to reduce adjusted earnings per share.
Margin pressure
Rising component costs for printed circuit boards and adverse currency movements are prompting more conservative gross margin assumptions and could squeeze profitability.
